SCHEMBL6356715

SCHEMBL6356715

O=C(NCc1c(O)cccc1Cl)c1cccc(Cl)c1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
HPGD P15428 2/20 0.49
P2RX7 Q99572 4/20 0.49
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
TAS1R2 Q8TE23 1/20 0.49
MT-CO2 P00403 1/20 0.47
TMEM97 Q5BJF2 2/20 0.46
SIGMAR1 Q99720 2/20 0.46
GPR139 Q6DWJ6 1/20 0.46
TSHR P16473 1/20 0.46
JAK2 O60674 1/20 0.46
ALDH1A1 P00352 2/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
ERCC5 P28715 1/20 0.45
FEN1 P39748 1/20 0.45
DRD2 P14416 1/20 0.44
DRD3 P35462 1/20 0.44
HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6362683 0.84 ATM (0.55) LMNAHPGDP2RX7TAS1R3TAS1R1
SCHEMBL6358813 0.84 MT-CO2 (0.65) LMNAHPGDP2RX7TAS1R3TAS1R1
SCHEMBL5645103 0.80 HPGD (0.62) LMNAHPGDP2RX7ALDH1A1MAPT
SCHEMBL6357279 0.80 HPGD (0.63) LMNAHPGDP2RX7TAS1R3TAS1R1
SCHEMBL6357294 0.80 L3MBTL1 (0.55) LMNAHPGDP2RX7TAS1R3TAS1R1
SCHEMBL14081423 0.78 MT-CO2 (0.65) LMNAHPGDMT-CO2HSP90AA1
SCHEMBL6354490 0.78 LMNA (0.74) LMNAHPGDP2RX7TMEM97SIGMAR1
SCHEMBL9491955 0.77 TAS1R3 (0.57) LMNAHPGDP2RX7TAS1R3TAS1R1
SCHEMBL4158170 0.76 TAS1R3 (0.64) LMNAHPGDP2RX7TAS1R3TAS1R1
SCHEMBL11570780 0.76 TAS1R3 (0.55) LMNAHPGDP2RX7TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 LMNA 1197/4885HPGD 586/4885P2RX7 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.